Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Drugs
Published in: Pediatric Drugs 4/2003

01-04-2003 | Therapy In Practice

Ribosomal Immunotherapy for Recurrent Respiratory Tract Infections in Children

Authors: Professor Marie C. Béné, Gilbert C. Faure

Published in: Pediatric Drugs | Issue 4/2003

Login to get access

Abstract

Recurrent respiratory tract infections are common in children. They reflect the immaturity of the immune system in its encounter with environmental antigens. Little or no specific protective immune response has yet been established. These infections represent an important public health problem in terms of both treatment (anti-inflammatory or antibacterial drugs for children) and economy.
Immunotherapy has been proposed as a means of preventing these recurrent infections by providing children with small doses of inactive bacterial antigens liable to trigger specific and protective immune responses. Among such drugs, ribosomal preparations (to which this review is limited) appear to be not only well tolerated, but also ideally targeted to induce mucosal responses. One preparation of ribosomal mucosal vaccine is commercially available in several countries. Numerous clinical trials in the world have confirmed the positive role of this mucosal ribosomal bacterial vaccine in significantly reducing the number of infections, courses of antibacterials, and absenteeism. In vitro and ex vivo investigations have confirmed that such vaccines indeed trigger protective specific immune responses.
Literature
1.
Fendrick AM, Saint S, Brook I, et al. Diagnosis and treatment of upper respiratory tract infections in the primary care setting. Clin Ther 2001; 23: 1683–706PubMedCrossRef
2.
Peat JK, Keena V, Harakeh Z, et al. Parental smoking and respiratory tract infections in children. Paediatr Respir Rev 2001; 2: 207–13PubMedCrossRef
3.
Mogyoros M. Challenges of managed care organizations in treating respiratory tract infections in an age of antibiotic resistance. Am J Manag Care 2001; 7(6 Suppl.): S163–169PubMed
4.
MacDonald TT, Spencer J. Ontogeny of the mucosal immune response. Springer Semin Immunopathol 1990; 12: 129–37PubMed
5.
Hanson LA, Ceafalau L, Mattsby-Baltzer I, et al. The mammary gland-infant intestine immunologic dyad. Adv Exp Med Biol 2000; 478: 65–76PubMedCrossRef
6.
Ritchie RF, Palomaki GE, Neveux LM, et al. Reference distributions for immunoglobulins A, G, and M: a practical, simple, and clinically relevant approach in a large cohort. J Clin Lab Anal 1998; 12: 363–70PubMedCrossRef
7.
Gorfien JL, Hard R, Noble B, et al. Quantitative study of germinal center area in normal and diseased tonsils using image analysis. Ann Otol Rhinol Laryngol 1999; 108: 398–402PubMed
8.
Kyd JM, Cripps AW. Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview. Vaccine 1999; 17: 1775–81PubMedCrossRef
9.
Pace JL, Rossi HA, Esposito VM, et al. Inactivated whole-cell bacterial vaccines: current status and novel strategies. Vaccine 1998; 16: 1563–74PubMedCrossRef
10.
Derenne JP, Delclaux B. Clinical experience with OM-85 BV in upper and lower respiratory tract infections. Respiration 1992; 59Suppl. 3: 28–31PubMedCrossRef
11.
Youmans AS, Youmans GP. Immunogenic activity of a ribosomal fraction obtained from Mycobacterium tuberculosis. J Bacteriol 1965; 89: 1291–8PubMed
12.
13.
Fujimura Y. Evidence of M-cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch 2000; 436: 560–6PubMedCrossRef
14.
Neutra MR. Current concepts in mucosal immunity: V role of M cells in transepithelial transport of antigens and pathogens to the mucosal immune system. Am J Physiol 1998; 274: G785–791PubMed
15.
Kraal G, Mebius RE. High endothelial venules: lymphocyte traffic control and controlled traffic. Adv Immunol 1997; 65: 347–95PubMedCrossRef
16.
Caliot E, Libon C, Kernels S, et al. Translocation of ribosomal immunostimulant through an in vitro-reconstituted digestive barrier containing M-like cells. Scand J Immunol 2000; 52: 588–94PubMedCrossRef
17.
Béné MC, Zanin C, Perrin P, et al. Specific antibody-producing cells in humans after oral immunization with a ribosomal vaccine Ribomunyl. Adv Exp Med Biol. 1995; 371B: 1563–6PubMed
18.
Zanin C, Perrin P, Béné MC, et al. Antibody-producing cells in peripheral blood and tonsils after oral treatment of children with bacterial ribosomes. Int J Immunopharmacol 1994; 16: 497–505PubMedCrossRef
19.
Kolopp-Sarda MN, Béné ME, Allaire JM, et al. Kinetics of specific salivary IgA responses in man after oral challenge by ribosomal immunostimulant. Int J Immunopharmacol 1997; 19: 181–6PubMedCrossRef
20.
Hbabi-Haddioui L, Roques C. Inhibition of Streptococcus pneumoniae adhesion by specific salivary IgA after oral immunisation with a ribosomal immunostimulant. Drugs 1997; 54Suppl. 1: 29–32PubMedCrossRef
21.
Michel FB, Dussourd d’Hinterland L, Pinel AM, et al. Prevention of bacterial respiratory infection by an association of bacterial ribosomes and membranous proteoglycans (II): objective assessment of the response and of the immunological stimulation. Arzneimittel Forschung 1980; 30: 198–206PubMed
22.
Girard JP, Gumowski PI, Chavaz A, et al. Rôle de différentes formes de Ribomunyl dans les infections respiratoires récidivantes. Schweiz Med Wochenschr 1988; 118: 856–61PubMed
23.
Fiocchi A, Vignati B, Cinquepalmi P, et al. Treatment using immucytal in children with recurrent respiratory infections: an Italian multicenter experience. Pediatr Med Chir 1989; 11: 285–91PubMed
24.
Fiocchi A, Arancio R, Cinquepalmi P, et al. Recurrent respiratory infections in childhood: experience with a bacterial extract plus bacterial ribosomes (Immucytal). J Int Med Res 1990; 18: 50–60PubMed
25.
Venturi MC, Biolchini A, Bardare M. Local immunotherapy prevention of recurrent respiratory infections in children. Minerva Pediatr 1991; 43: 557–61PubMed
26.
Gordienko SM, Lasitsa OI, Misharina ZA, et al. The correction of the immune system by using the immunomodulator ribomunyl in patients with recurrent respiratory tract infections [in Russian]. Ter Arkh 1995; 67: 32–8PubMed
27.
Mora R, Barbieri M, Passali GC, et al. A preventive measure for otitis media in children with upper respiratory tract infections. Int J Pediatr Otorhinolaryngol 2002; 63: 111–8PubMedCrossRef
28.
Serrano E, Demanez JP, Morgon A, et al. Effectiveness of ribosomal fractions of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and the membrane fraction of Kp (Ribomunyl®) in the prevention of clinical recurrences of infectious rhinitis: results of a multicenter double-blind placebo-controlled study. Eur Arch Otorhinolaryngol 1997; 254: 372–5PubMedCrossRef
29.
Boyle P, Bellanti JA, Robertson C. Meta-analysis of published clinical trials of a ribosomal vaccine (Ribomunyl®) in prevention of respiratory infections. Biodrugs 2000; 14: 389–408PubMedCrossRef
30.
Simecka JW. Mucosal immunity of the gastrointestinal tract and oral tolerance. Adv Drug Deliv Rev 1998; 34: 235–59PubMedCrossRef
31.
32.
33.
Banz K, Schwicker D, Thomas AM. Economic evaluation of immunoprophylaxis in children with recurrent ear, nose and throat infections. Pharmacoeconomics 1994; 6: 464–77PubMedCrossRef
Metadata
Title
Ribosomal Immunotherapy for Recurrent Respiratory Tract Infections in Children
Authors
Professor Marie C. Béné
Gilbert C. Faure
Publication date
01-04-2003
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 4/2003
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.2165/00128072-200305040-00002

Other articles of this Issue 4/2003

Pediatric Drugs 4/2003 Go to the issue

Review Article

Child and Adolescent Suicide

Therapy In Practice

Prediabetes in Children

Review Article

Pharmacokinetic Considerations in the Treatment of Childhood Epilepsy

Therapy In Practice

Pain Management in Children with Sickle Cell Disease